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ess: r.a.stockley@bhamSummary It is unclear how chronic expectoration influences airway inflammation
in patients with chronic lung disease. The aim of this study was to investigate factors
influencing inflammation in induced sputum samples, including, in particular, chronic
sputum production. Myeloperoxidase, interleukin-8, leukotriene B4 (LTB4), neutro-
phil elastase, secretory leukoprotease inhibitor (SLPI) and protein leakage were
compared in induced sputum samples from 48 patients (36 with chronic expectora-
tion) with COPD (with and without alpha-1-antitrypsin deficiency; AATD), 9
individuals with AATD but without lung disease and 14 healthy controls. There were
no differences in inflammation in induced sputum samples from healthy control
subjects and from AATD deficient patients with normal lung function but without
chronic expectoration (P40:05). Inflammation in induced sputum from AATD
patients with airflow obstruction and chronic sputum expectoration was significantly
greater than for similar patients who did not expectorate: Interleukin-8 (Po0:01),
elastase activity (P ¼ 0:01), and protein leakage (Po0:01). The presence of
spontaneous sputum expectoration in AATD patients with airflow obstruction was
associated with increased neutrophilic airway inflammation in induced sputum
samples. The presence of chronic expectoration in some patients will clearly
complicate interpretation of studies employing sputum induction where this feature
has not been identified.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserve
ant from Bayer as part of
nt of Medicine, Queen
Birmingham NHS Founda-
nd, UK.
8256.
.ac.uk (R.A. Stockley).Introduction
The pathophysiology of COPD is thought to be
related to inflammatory processes occurring within
the airway wall and lumen that may be more
pronounced in susceptible smokers. Early investiga-
tions in COPD involved the use of bronchoalveolar
lavage (BAL) to harvest secretions from thed.
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Expectoration and inflammation 1095peripheral airways and alveolar region,1–3 in order
to determine their relationship to the presence of
emphysema. Subsequent studies have often em-
ployed the assessment of expectorated secretions
because of the invasive nature of BAL.4–6 However,
many patients with COPD do not expectorate
spontaneously and for this reason sputum induction
has been used as an alternative and has confirmed
that patients with COPD have increased inflamma-
tion7–9 although poor patient characterisation has
made interpretation of the data difficult. In
addition, the relationships between these findings
and the pathophysiology of the small airways and
the alveolar region are unknown.
Studies using expectorated samples from patients
with alpha (a)-1-antitrypsin deficiency (AATD) have
confirmed that inflammation is also increased in the
larger airways of these subjects.4 In particular, the
inflammation appears to be greater than in samples
from non-deficient patients otherwise matched for
physiological impairment and is consistent with the
more rapid progression seen in AATD patients. The
inflammation appears to be related to an increase in
the chemoattractant leukotriene B4 (LTB4), which
has also been found in BAL fluid from deficient
patients.10 It is possible, therefore, that the
inflammation in the major airways mirrors the
inflammation occurring at the bronchoalveolar level
(at least in AATD); however, it is unclear whether the
increased inflammation is a feature of AATD itself or
is simply an indicator of the bronchitis associated
with chronic sputum expectoration. The aim of this
study was therefore to investigate the factors that
influence the level of inflammation observed in
induced sputum samples including chronic sputum
production, AATD and airflow obstruction. Some of
the results of these studies have been previously
reported in the form of an abstract.11Methods
Patients
Induced sputum samples were collected from
stable patients (no antibiotics or oral corticoster-
oids for X2 months) with COPD (FEV1o80%
predicted; FEV1/FVC ratio o70% and o15% rever-
sibility; CT scan consistent with emphysema) with
(PiZ) and without (PiM) AATD. Healthy controls
were recruited from hospital and University staff
with no history of lung or other systemic disease or
long-term treatment. Individuals with AATD but
without lung disease were identified through family
screening and shown to have normal lung function.
Deficiency was associated with serum a-1-antitryp-sin concentrations less than 11 mM,12 all subjects
were of the PiZ phenotype and no patient had ever
received AAT augmentation therapy.
Samples were obtained from 48 patients with the
characteristics given above (i.e. FEV1o80%; o15%
reversibility; CT scan consistent with emphysema)
of whom 36 fulfilled standard criteria for chronic
bronchitis with daily expectoration for at least 2
years (14 PiZ, 22 PiM). The remaining 12 (all PiZ) did
not expectorate regularly. Nine further individuals
with AATD but no physiological evidence of lung
disease and 14 healthy controls also provided
samples.
Induced sputum
After rinsing their mouths and blowing their noses,
patients inhaled hypertonic saline [Devilbiss Ultra-
Neb 2000] at 6ml/min until at least 5ml of
expectorant had been obtained. The entire sample
was ultracentrifuged (50,000g; 4 1C; 90min) and the
sol was stored at 701, together with serum
obtained from venous blood (10ml). Biochemical
assays were performed as described in detail else-
where and all samples had mediator measurements
above the lower limit of detection.5 Myeloperox-
idase (MPO) activity was measured by chromogenic
assay, interleukin-8 (IL-8) and LTB4 by ELISA, and
neutrophil elastase activity using the substrate
methoxysuccinyl-ala-ala-pro-val-paranitroanilide.
Secretory leukoprotease inhibitor was measured by
ELISA and protein leakage was assessed using
sputum/serum ratios for albumin (%).
Statistics
Results are reported as mean (SE). The Wilcoxon
rank sum test for non-paired data with a correction
factor for multiple comparisons was used to
compare subject groups and a value of Pp0:05
was considered statistically significant. The SPSS
statistical package was used (version 11.0; Illinois).
The institutional review board for human studies
approved the protocol and informed written con-
sent was obtained from the subjects.Results
Factors affecting inflammation in induced
sputum samples
AATD in patients with normal lung function
The healthy control subjects (Table 1, Group A) and
AATD subjects with no lung disease (Group B) had
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Table 1 Demographics and pulmonary physiology.
Group A B C D E
AATD  +  + +
COPD   + + +
CB   +  +
N 14 9 22 12 14
Age (years) 45.6 (5.2) 39.8 (2.4) 65.8**** (1.4) 56.3zz (1.9) 52.4 (2.1)
Male 4 (29%) 7z (78%) 12 (55%) 7 (58%) 11 (79%)
FEV1 (%) 92.5 (3.2) 113.1 (11.6) 38.9 (2.4) 34.5
zz (4.7) 33.2 (3.9)
FEV1 /FVC (%) 87.8 (2.2) 92.1 (4.8) 41.3 (2.7) 41.8
zz (3.9) 37.9 (3.2)
DLCO/VA (%) n/a 91.6 (5.9) 60.8 (4.9) 55.5
zz (5.8) 49.9 (5.6)
Smoking
Current 0 0 4 (18%) 1 (8%) 2 (14%)
Non 11 (79%) 4 (44%) 0 1 (8%) 1 (7%)
Ex 3 (21%) 5 (56%) 18 (82%) 10 (84%) 11 (79%)
Inhaled Steroids 0 0 14 (64%) 9zz (75%) 10 (71%)
The first 4 rows of the table indicate the characteristics of the patient groups, which are each identified by a letter (A–E). The
‘‘+’’ sign indicates the presence and the ‘‘’’ sign, the absence of a different diagnostic characteristic. AATD, alpha-1-
antitrypsin deficiency; COPD, chronic obstructive pulmonary disease; CB, chronic bronchitis. Pulmonary function data (FEV1,
FVC, DLCO/VA) are expressed as a percentage of the predicted value for age, height, and sex. The following comparisons were
made: Groups A and D vs. B; Groups C and D vs. E. The symbols indicate significant differences between the patient groups:
Group A vs. B zPo 0.05; Group D vs. B zzPo0.001. Group C vs. E ****Po 0.001. N/a, no data available.
Table 2 Airway inflammation in induced sputum samples.
Group A B C D E
AATD  +  + +
COPD   + + +
CB   +  +
MPO (Units/ml) 0.370.02 0.370.05 0.270.04**** 0.370.05 0.670.13
Elastase (nM) 0.270.01 0.270.07 2.071.9**** 0.170.02 22.1721.3y
IL-8 (nM) 0.870.3 0.770.2 3.271.2* 1.070.2z 4.571.5yy
LTB4 (nM) 13.774.0 15.275.5 7.873.1** 7.971.9 23.577.9
SLPI (mM) 1.270.2 2.571.0 1.870.3 2.570.5 2.670.8
Sputum/serum albumin ratio (%) 0.470.1 0.570.1 0.870.3*** 0.370.0 0.870.1yy
The first 4 rows of the table indicate the characteristics of the patient groups, which are each identified by a letter (A–E). The
‘‘+’’ sign indicates the presence and the ‘‘’’ sign, the absence of a different diagnostic characteristic. AATD, alpha-1-
antitrypsin deficiency; COPD, chronic obstructive pulmonary disease; CB, chronic bronchitis.
The data are presented as mean7SE. The following comparisons were made: Groups A and D vs. B; Groups C and D vs. E. The
symbols indicate significant differences between the patient groups: Group D vs. B zPo0.05; Group C vs. E *P ¼ 0.05, **Po0.05,
***Po0.01, ****Po0.001. Group D vs. E yP ¼ 0.01 and yyPo0.01.
S. Gompertz et al.1096similar clinical characteristics, with no differences
in age, spirometry, smoking status or inhaled
steroid prescription (Table 1; P40:05). There were,
however, more men in the AATD group (Po0:05).
The induced sputum data for these 2 groups are
summarised in Table 2; there were no significant
differences in any of the airway inflammatory
parameters (P40:05 for all comparisons).
AATD in patients with COPD
Inflammation in sputum induction samples was
compared between patients with COPD and chronicsputum production without (Group C) and
with AATD (Group E). Those with AATD were
younger (Po0:001), although the remainder
of their clinical characteristics including their
average spirometry and gas transfer were not
significantly different (P40:05). The patients
with AATD had more inflammation (Fig. 1 and
Table 2), with higher concentrations of MPO
(Po0:001), IL-8 (P ¼ 0:05), and LTB4 (Po0:05).
They also had greater albumin leakage (Po0:01)
and elastase activity (Po0:001) than those without
deficiency.
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Figure 1 Effect of a-1-antitrypsin deficiency on inflam-
mation in induced sputum samples. The graphs above
illustrate the concentrations of MPO, IL-8 and LTB4 and
sputum:serum albumin ratio, respectively, in induced
sputum from patients with COPD and chronic bronchitis
with (Group E) and without (Group C) AATD. The
inflammatory parameters are recorded on a logarithmic
scale. The horizontal bars indicate the mean values, the
closed circles represent individual data points for
patients in Group E, and the open circles represent
patients in Group C. The asterisks highlight significant
differences between the 2 groups of patients: *P ¼ 0:05,
**Po0:05, ***Po0:01, ****Po0:001.
Expectoration and inflammation 1097Chronic sputum production
A comparison of airway inflammation was made
between 2 groups of patients with AATD who had a
similar degree of airway obstruction but varying in
the absence (Group D) or presence (Group E) ofchronic bronchitis with daily expectoration for at
least 2 years. There were no significant differences
in any of the clinical characteristics summarised in
Table 1 (P40:05).
The samples from the patients with chronic
bronchitis had higher concentrations of IL-8
(Po0:01), greater elastase activity (P ¼ 0:01),
and an increased sol/serum albumin ratio
(Po0:01; Table 2). Although the mean concentra-
tions of MPO and LTB4 were also higher in those
with chronic bronchitis, they did not reach con-
ventional statistical significance (P40:05).Airflow obstruction
Patients with AATD but with neither sputum
production nor airflow obstruction (Group B) were
younger than the subjects with COPD and AATD who
did not have daily sputum production (Group D;
Po0:001). Those with airflow obstruction had a
lower FEV1 and FEV1/FVC ratio by definition and a
reduced gas transfer consistent with emphysema
(Po0:001 for all comparisons). A significantly
greater proportion were also receiving inhaled
corticosteroids (Po0:001). The remainder of their
clinical parameters (summarised in Table 1) were
no different (P40:05).
The induced sputum results revealed no differ-
ences in the concentrations of MPO, elastase
activity, LTB4, SLPI or sputum albumin between
the two groups (all P40:05). IL-8 levels were,
however, higher in the patients with obstructive
lung disease (Po0:05). These results are sum-
marised in Table 2.Discussion
Previous studies have demonstrated that airway
inflammatory parameters measured in spontaneous
sputum sample are increased in AATD4 and the
present study confirms that this is also the case
when airway inflammation is measured in induced
sputum samples providing the patients expectorate
spontaneously.
The subsequent findings, however, have major
implications for the use of sputum induction in the
assessment of patients with and without chronic
spontaneous expectoration. The comparisons be-
tween AATD subjects with and without chronic
expectoration indicate that the concentration of
IL-8, as well as elastase activity and albumin
leakage are significantly higher in those individuals
with spontaneous sputum production. Although the
concentrations of MPO and LTB4 were also higher,
these did not reach statistical significance in this
ARTICLE IN PRESS
S. Gompertz et al.1098study. Nevertheless the presence of spontaneous
sputum expectoration in AATD is associated with a
general increase in the concentrations of several
neutrophilic airway inflammatory parameters in the
induced samples, even in patients with a similar
degree of airflow obstruction. The results suggest
that the presence of chronic expectoration in some
patients with COPD will therefore complicate the
interpretation of studies employing sputum induc-
tion where this feature has not been explicitly
identified. The present results are in keeping with
the findings of lavage studies, which have also
demonstrated more inflammatory cells in the air-
ways of smokers with chronic expectoration than
those without.2,13
The significance of the effect of spontaneous
sputum expectoration is further highlighted by the
data obtained from patients with AATD but no lung
disease and from normal healthy subjects. The
inflammatory parameters measured in these groups
were similar to those measured in induced sputum
samples from AATD patients with COPD but without
sputum expectoration (with the exception of
increased IL-8 in the obstructed AATD group). Since
patients with AATD and lung disease show contin-
ued progression of their emphysema14 and even
those with normal lung function and AATD have
increased inflammation in lavage samples,10 the
lack of a difference in induction samples between
these groups has implications for the investigation
and pathophysiology of COPD. It suggests that
sputum induction does not provide direct informa-
tion about the inflammation that is related to the
development of the peripheral airway obstruction
associated with emphysema. Furthermore, in-
creased inflammation detected in induced sputum
samples appears to be a feature of patients with
cough and sputum expectoration and not related to
the presence or absence of airflow obstruction.
Thus in studies of patients with COPD (whether with
or without AATD) it is critical to document the
presence or absence of spontaneous sputum ex-
pectoration and to take this into account in order
to interpret the results correctly.
It is possible that some of the data presented
here may have been influenced by the patients’
concomitant treatment. For instance, 75% of those
with AATD and COPD but without sputum produc-
tion were receiving inhaled corticosteroids. An
anti-inflammatory effect may have attenuated
any differences from those without lung disease
(who were not receiving inhaled steroids). Although
the efficacy of steroids remains unclear15–19 an
anti-inflammatory effect has been demonstrated
when patients expectorating sputum have been
studied.16 However, this may not be the case insubjects who do not expectorate and therefore
have less airway inflammation prior to treatment.
Finally, it is of interest that the only difference
found in COPD patients with AATD who do not
expectorate compared to normal subjects and AATD
patients without lung disease is the IL-8. Studies of
early pre-clinical emphysema found that lavage IL-
8 was increased and implicated this cytokine in the
pathogenesis.20 Since AATD is predominately asso-
ciated with emphysema it is possible that the high
IL-8 value found in the present study represents a
more anatomically widespread airway abnormality
thereby reflecting the processes occurring in the
more distal airways. Although the average differ-
ence is small the local concentration of IL-8 in the
airway may be both optimal for neutrophil migra-
tion in AATD or sufficiently different to increase
neutrophil migration. Even if this latter effect is
small the continued stream of increased numbers of
neutrophils over days and years may be the sole
reason for developing the progressive airflow
obstruction in these patients. Clearly, further
studies are required to assess this possibility in
detail.
In summary, the results from the current study
suggest that the increased inflammation found in
COPD when using sputum induction may be depen-
dant on some or all of the patients being
spontaneous sputum expectorators and thus biasing
the group data. Future studies using sputum
induction to assess airway inflammation will need
to take this into account. Finally, in the absence of
sputum expectoration the results of induced
sputum analysis do not demonstrate increased
inflammation in subjects with COPD related to
AATD (apart from an increase in IL-8), suggesting
secretions obtained by this method may not reflect
pathological processes at alveolar level.References
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